Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer
Lijie Zhang, Jingwen Wang, Juefeng Wan, Yan Wang, Hui Zhang, Yaqi Wang, Fan Xia, Lijun Shen, Zhen Zhang · 2026
Read Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer by Lijie Zhang, Jingwen Wang, Juefeng Wan, Yan Wang, Hui Zhang, Yaqi Wang, Fan Xia, Lijun Shen, Zhen Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13530517.txt.
Description
Lijie Zhang and co-authors look for signs that predict how rectal cancer will respond to treatment given before surgery. Their 2026 study drew on 437 patients treated at a cancer center in Shanghai between 2019 and 2023. Most tumors were of the microsatellite-stable type, the group named in the title. Gene tests on tumor and normal samples used a panel of 887 genes.
In the main group, about one third of patients had a complete response. A treatment plan that paired standard care with immunotherapy raised the odds of that result, as did a mutation in the SYNE1 gene. A mutation in KRAS pointed the other way for long term health, with one subtype linked to spread to the lungs. The team built a chart that joins clinic and gene data.
Catalog record
| CREATOR | Lijie Zhang, Jingwen Wang, Juefeng Wan, Yan Wang, Hui Zhang, Yaqi Wang, Fan Xia, Lijun Shen, Zhen Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |